Tallac Therapeutics Funding: $62M Raised, Series A (2020)
Tallac Therapeutics is based in Burlingame. It has raised $62M in total funding. Latest round: Series A.
Tallac Therapeutics funding overview
Tallac Therapeutics is based in Burlingame. Tallac Therapeutics has raised $62M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in December 2020. The round record for Tallac Therapeutics runs through 2020; nothing later has been disclosed. Investors on record include venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China, MRL Ventures Fund. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Tallac Therapeutics funding
How much has Tallac Therapeutics raised?
Tallac Therapeutics has raised $62M in total disclosed funding across the rounds on record.
Who has invested in Tallac Therapeutics?
venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China, MRL Ventures Fund are named among the investors backing Tallac Therapeutics.
What was the latest Tallac Therapeutics funding round?
The most recent disclosed round is a Series A, announced in December 2020.
Where is Tallac Therapeutics based?
Tallac Therapeutics is based in Burlingame.
When did Tallac Therapeutics last raise?
The last disclosed Tallac Therapeutics round closed in December 2020 at Series A.
Totals shown for Tallac Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Burlingame and the investors behind them below.
